OTCMKTS:BSTG

Biostage Stock Forecast, Price & News

$1.22

+0.06 (+5.17 %)

(As of 01/15/2021 08:27 PM ET)

Add

Compare

Today's Range

$1.18

Now: $1.22▼

$1.34

50-Day Range

$1.10

MA: $1.29▼

$1.45

52-Week Range

$0.80

Now: $1.22▼

$4.88

Volume8,600 shs

Average Volume3,770 shs

Market Capitalization$11.46 million

P/E RatioN/A

Dividend YieldN/A

Beta0.04

Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.

Overall MarketRank^™

0.56 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Biostage.

2.8 Community Rank

Outperform Votes
Biostage has received 51 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Biostage has received 40 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Biostage has received 56.04% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Biostage and other stocks. Vote “Outperform” if you believe BSTG will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BSTG will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Biostage does not currently pay a dividend.
Dividend Growth
Biostage does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biostage insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.70% of the stock of Biostage is held by insiders.
Percentage Held by Institutions
Only 0.27% of the stock of Biostage is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Biostage is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biostage is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Biostage has a P/B Ratio of 9.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:BSTG

Previous Symbol

CUSIPN/A

CIK1563665

Webwww.biostage.com

Phone774-233-7300

Employees7

Debt

Debt-to-Equity Ratio0.09

Current Ratio3.33

Quick Ratio3.33

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.13 per share

Price / Book9.38

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-8,330,000.00

Net MarginsN/A

Return on Equity-547.84%

Return on Assets-268.41%

Miscellaneous

Outstanding Shares9,390,000

Market Cap$11.46 million

Next Earnings Date3/26/2021 (Estimated)

OptionableNot Optionable

$1.22

+0.06 (+5.17 %)

(As of 01/15/2021 08:27 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive BSTG News and Ratings via Email

Sign-up to receive the latest news and ratings for BSTG and its competitors with MarketBeat's FREE daily newsletter.

Biostage (OTCMKTS:BSTG) Frequently Asked Questions

How has Biostage's stock price been impacted by COVID-19 (Coronavirus)?

Biostage's stock was trading at $3.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BSTG shares have decreased by 65.1% and is now trading at $1.22.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than Biostage?

Wall Street analysts have given Biostage a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biostage wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Biostage's next earnings date?

Biostage is scheduled to release its next quarterly earnings announcement on Friday, March 26th 2021.
View our earnings forecast for Biostage.

How were Biostage's earnings last quarter?

Biostage, Inc. (OTCMKTS:BSTG) announced its earnings results on Friday, November, 13th. The company reported ($0.07) earnings per share (EPS) for the quarter.
View Biostage's earnings history.

Who are some of Biostage's key competitors?

Some companies that are related to Biostage include Motus GI (MOTS), Neovasc (NVCN), Aethlon Medical (AEMD), Arch Therapeutics (ARTH), InspireMD (NSPR), Hancock Jaffe Laboratories (HJLI), Ra Medical Systems (RMED), InVivo Therapeutics (NVIV), Interpace Biosciences (IDXG), INVO Bioscience (INVO), Dynatronics (DYNT), NeuroMetrix (NURO), Obalon Therapeutics (OBLN), Plus Therapeutics (PSTV) and Lianluo Smart (LLIT).
View all of BSTG's competitors.

What other stocks do shareholders of Biostage own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biostage investors own include Fulcrum Therapeutics (FULC), Allena Pharmaceuticals (ALNA), VIVUS (VVUS), Aldeyra Therapeutics (ALDX), Arbutus Biopharma (ABUS), Akero Therapeutics (AKRO), Ampliphi Biosciences (APHB), Ardelyx (ARDX), Armata Pharmaceuticals (ARMP) and Athersys (ATHX).

Who are Biostage's key executives?

Biostage's management team includes the following people:

Mr. Yu Hong, Pres (Age 47, Pay $157.95k)
Dr. William L. Fodor Ph.D., Chief Scientific Officer (Age 61, Pay $322.15k)
Mr. James Mastridge, Interim VP of Fin., Principal Accounting Officer & Principal Financial Officer (Age 54)
Dr. Shunfu Hu Ph.D., VP of Bus. Devel. & Operations

What is Biostage's stock symbol?

Biostage trades on the OTCMKTS under the ticker symbol "BSTG."

How do I buy shares of Biostage?

Shares of BSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biostage's stock price today?

One share of BSTG stock can currently be purchased for approximately $1.22.

How big of a company is Biostage?

Biostage has a market capitalization of $11.46 million. Biostage employs 7 workers across the globe.

What is Biostage's official website?

The official website for Biostage is www.biostage.com.

How can I contact Biostage?

Biostage's mailing address is 84 October Hill Road Suite 11, Holliston MA, 01746. The company can be reached via phone at 774-233-7300 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here